Palatin Announces Two Presentations at the 2021 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
Positive clinical data from its Phase 2 study of PL9643 in dry eye disease
Pre-clinical data with melanocortins for retinal inflammation
News provided by
Share this article
Share this article
CRANBURY, N.J., April 20, 2021 /PRNewswire/ Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin peptide receptor system, today announced two presentations of the Company s melanocortin platform, including PL9643 in dry eye disease, at the Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting, being held virtually May 1-7, 2021.